Dronabinol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dronabinol: From an Unspecified Original Indication to Migraine Disorder
One-Sentence Summary
Dronabinol is a synthetic Δ9-THC (CB1/CB2 receptor agonist); the evidence pack does not document its original approved indication or a US marketing history in this dataset. The TxGNN model predicts it may be effective for Migraine Disorder, with 7 clinical trials (including one completed dronabinol-specific Phase 2 RCT) and 13 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (original indication and MOA are flagged as data gaps) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for the original indication is not available (DG002, High severity gap). Based on the pharmacological information available in the evidence pack, dronabinol is a synthetic Δ9-tetrahydrocannabinol (THC) and a CB1/CB2 cannabinoid receptor agonist.
The rationale for a migraine indication rests on the “clinical endocannabinoid deficiency” hypothesis: CB1 receptors are expressed on the trigeminovascular system and trigeminal ganglion, and endogenous cannabinoids (e.g., anandamide) are thought to modulate CGRP release and central sensitization — both central to migraine pathophysiology. This gives the prediction moderate-to-strong mechanistic plausibility.
However, most of the supporting clinical and literature evidence comes from inhaled/vaporized cannabis or multi-cannabinoid combinations (THC+CBD, THC+CBD+CBG) rather than purified dronabinol itself, so there is a meaningful gap between the drug entity being evaluated and the interventions actually studied. Only one completed trial (NCT00123201) and one case report (PMID 19220500) specifically name dronabinol.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00123201 | Phase 2 | Completed | N/A | Multicenter, randomized, double-blind, placebo-controlled study evaluating dronabinol MDI efficacy and safety for acute treatment of moderate-to-severe migraine headache. |
| NCT04360044 | Phase 2 | Completed | 92 | Crossover RCT of vaporized THC, THC/CBD mix, and CBD vs placebo for acute migraine treatment. |
| NCT05427630 | Phase 2 | Suspended | 20 | Pilot dose-ranging crossover trial of 3 inhaled cannabis potencies (2.5%/5%/10%) vs placebo for acute migraine; suspended, no results yet. |
| NCT04989413 | Phase 2/3 | Terminated | 110 | CBD 133mg + CBG 66mg + THC 4mg/day as adjunctive therapy in chronic migraine; terminated before completion. |
| NCT05337033 | Phase 2 | Recruiting | 20 | Multicenter tolerability study of CBD-enriched cannabis herbal extract in adolescents with chronic headaches (including migraine). |
| NCT07146945 | Phase 1 | Not yet recruiting | 84 | Safety, tolerability and PK of single ascending doses of S1-221 (oral CBD+THC liquid) in healthy adults; not migraine-specific. |
| NCT04091789 | Phase 2 | Unknown | 30 | Sublingual cannabinoid combination tablet for dysmenorrhea pain; tangential to migraine, follow-up status unknown. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41469488 | 2026 | RCT | Headache | Randomized, double-blind, placebo-controlled crossover trial evaluating vaporized cannabis efficacy for acute migraine. |
| 31715263 | 2020 | Review | The Journal of Pain | Analysis of real-world data on inhaled cannabis effects on headache/migraine ratings, examining dose, THC/CBD content, and tolerance. |
| 32758396 | 2020 | Cohort/Observational | Journal of Integrative Medicine | Real-time tracking study of dried cannabis flower use showing symptom relief for headache and migraine under naturalistic conditions. |
| 29797104 | 2018 | Cohort/Survey | The Journal of Headache and Pain | Medicinal cannabis cohort survey identifying usage patterns and medication substitution among migraine/headache patients. |
| 39988876 | 2025 | Preclinical (mice) | Cephalalgia | CBD+THC combination alleviated migraine-like behaviors triggered by CGRP, sodium nitroprusside, and cortical spreading depolarization. |
| 41182862 | 2025 | Preclinical (mice) | Cephalalgia | 100:1 CBD:THC ratio mitigated central CGRP-induced migraine symptoms, supporting cannabinoid modulation of the CGRP pathway. |
| 29111112 | 2018 | Preclinical (rat) | European Journal of Pharmacology | THC produced anti-migraine effects in a TRPA1-agonist-induced dural pain model in female rats. |
| 34432530 | 2022 | Educational/Survey | Cannabis and Cannabinoid Research | Continuing-education study on nurse practitioner knowledge/confidence discussing cannabis with patients; not direct efficacy evidence. |
| 10575286 | 1999 | Survey | Forschende Komplementärmedizin | German-language survey on patterns of self-prescribed medical cannabis use, including pain and spasm indications. |
| 2997048 | 1985 | In vitro pharmacology | International Journal of Clinical Pharmacology Research | THC and CBD inhibited serotonin release from platelets exposed to plasma of migraine patients — an early mechanistic finding. |
US Market Information
Dronabinol currently shows no marketing authorization on file in this evidence pack (market status: not marketed, 0 licenses recorded).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The migraine indication has moderate mechanistic plausibility and one completed dronabinol-specific Phase 2 RCT (NCT00123201), supporting an L2 evidence level. However, a Blocking-severity data gap (DG001 — TFDA label warnings/contraindications unavailable) prevents this candidate from entering the safety pre-screening stage, and most supporting trials/literature studied cannabis or multi-cannabinoid products rather than dronabinol itself.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) to unblock the safety initial evaluation (DG001)
- Confirmed mechanism of action and original approved indication for dronabinol in this dataset (DG002)
- Drug interaction (DDI) data — current query returned no results
- Clarification of drug-specificity: prioritize dronabinol-specific trial data over cannabis/multi-cannabinoid combination studies when assessing efficacy
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.